Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | EYA2 | O00167 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1322891 | 0.97 | TDP1 (0.38) | TDP1EYA2APPACETP53 | |
| SCHEMBL11295988 | 0.97 | TDP1 (0.38) | TDP1EYA2APPACETP53 | |
| Ammonia Solution, Strong SCHEMBL3916100 | 0.97 | TDP1 (0.38) | TDP1EYA2APPACETP53 | |
| SCHEMBL3901854 | 0.97 | TDP1 (0.38) | TDP1EYA2APPACETP53 | |
| Acetic Acid SCHEMBL10723799 | 0.80 | — | — | |
| SCHEMBL22128524 | 0.80 | TP53 (0.33) | TDP1EYA2APPACETP53 | |
| SCHEMBL867976 | 0.80 | TDP1 (0.41) | TDP1EYA2APPACETP53 | |
| SCHEMBL16057464 | 0.79 | TDP1 (0.36) | TDP1EYA2APPACETP53 | |
| SCHEMBL8998280 | 0.79 | TDP1 (0.36) | TDP1EYA2APPACETP53 | |
| SCHEMBL8700152 | 0.79 | TDP1 (0.58) | TDP1EYA2APPACETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 848 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048155-A1 | BIOCOMPATIBLE PARAHYDROGEN HYPERPOLARIZED SOLUTIONS BY PRECIPITATION AND RE-DISSOLUTION | UNIV NORTH CAROLINA STATE (US) | 2026-02-19 | — | — | US | claimed |
| US-20240392009-A1 | PHARMACEUTICAL COMPOSITIONS FOR ANTIBODIES AND MAKING AND USING THE SAME | INVETX INC (US) | 2024-11-28 | — | — | US | claimed |
| US-12083117-B2 | Compositions and kits useful for treatment of respiratory illness | THE PROCTER & GAMBLE COMPANY (US) | 2024-09-10 | — | — | US | claimed |
| WO-2024044520-A1 | BIOCOMPATIBLE PARAHYDROGEN HYPERPOLARIZED SOLUTIONS BY PRECIPITATION AND RE-DISSOLUTION | NORTH CAROLINA STATE UNIVERSITY (US) | 2024-02-29 | — | — | WO | claimed |
| US-20230414760-A1 | PHARMACEUTICAL FORMULATION | ASTRAZENECA UK LIMITED (GB) | 2023-12-28 | — | — | US | claimed |
| US-20230364026-A1 | STABILIZED SOLID NANOPARTICLE FORMULATIONS OF CANNABINOIDS AND CANNABINOID ANALOGS WITH REDUCED OSTWALD RIPENING FOR ORAL, INHALATION, NASAL AND PARENTERAL DRUG DELIVERY | AUSTIN BIOSCIENCES CORP. | 2023-11-16 | — | — | US | claimed |
| EP-4243780-A1 | PHARMACEUTICAL FORMULATION | AstraZeneca UK Limited (GB) | 2023-09-20 | — | — | EP | claimed |
| EP-4213809-A1 | STABILIZED SOLID NANOPARTICLE FORMULATIONS OF CANNABINOIDS AND CANNABINOID ANALOGS WITH REDUCED OSTWALD RIPENING FOR ORAL, INHALATION, NASAL AND PARENTERAL DRUG DELIVERY | Luminus Biosciences Inc. (US) | 2023-07-26 | — | — | EP | claimed |
| US-20220370623-A1 | Nanoparticles Comprising Prodrugs Stabilized by Albumin for Treatment of Cancer and Other Diseases | AUSTIN BIOSCIENCES CORP. | 2022-11-24 | — | — | US | claimed |
| EP-4054550-A2 | NANOPARTICLES COMPRISING PRODRUGS STABILIZED BY ALBUMIN FOR TREATMENT OF CANCER AND OTHER DISEASES | Luminus Biosciences Inc. (US) | 2022-09-14 | — | — | EP | claimed |
| US-5693517-A | RNA TEMPLATE, DNA POLYMERASE, PRIMER, NUCLEOSIDE TRIPHOSPHATES, DIVALENT AND MONOVALENT CATIONS, BUFFERING AGENT | ROCHE MOLECULAR SYSTEMS, INC. (US) | 1997-12-02 | — | — | US | claimed |
| EP-0395346-B1 | Photosensitive composition | FUJI PHOTO FILM CO LTD (JP) | 1996-11-27 | — | — | EP | claimed |
| US-5561058-A | AMPLIFYING RNA TARGETS | HOFFMANN-LA ROCHE INC. (US) | 1996-10-01 | — | — | US | claimed |
| US-5019133-A | Method for dyeing polyester-containing fibers in an alkaline dyeing bath and dyeing assistant, an amino-acid compound | MITSUBISHI KASEI CORPORATION (JP) | 1991-05-28 | — | — | US | claimed |
| EP-0096654-B1 | PROCESS FOR SIZING PAPER WITH ANIONIC, HYDROPHOBIC SIZING AGENTS AND CATIONIC RETENTION AGENTS | CIBA-GEIGY AG (CH) | 1987-10-28 | — | — | EP | claimed |
| EP-0158556-B1 | PROCESS FOR THE PREPARATION OF HYDROXYALKYLAMINOACETIC ACIDS | SOCIETE FRANCAISE HOECHST Société anonyme dite: (FR) | 1987-07-01 | — | — | EP | claimed |
| EP-0158556-A1 | Process for the preparation of hydroxyalkylaminoacetic acids | SOCIETE FRANCAISE HOECHST Société anonyme dite: (FR) | 1985-10-16 | — | — | EP | claimed |
| EP-0096654-A2 | Process for sizing paper with anionic, hydrophobic sizing agents and cationic retention agents | CIBA-GEIGY AG (CH) | 1983-12-21 | — | — | EP | claimed |
| US-4297100-A | Aqueous dye preparations | CIBA-GEIGY CORPORATION (US) | 1981-10-27 | — | — | US | claimed |
| US-4192722-A | Composition and method for stannate plating of large aluminum parts | REYNOLDS METALS COMPANY (US) | 1980-03-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048155-A1 | BIOCOMPATIBLE PARAHYDROGEN HYPERPOLARIZED SOLUTIONS BY PRECIPITATION AND RE-DISSOLUTION | HNRNPR, SIGMAR1, MAP2K1 | TDP1 3286/4885EYA2 1885/4885APP 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.